Amgen (NASDAQ:AMGN) Stock Sold by Sen. Sheldon Whitehouse

Senator Sheldon Whitehouse (Democratic-Rhode Island) recently sold their entire stake in Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on November 2nd, the Senator disclosed that they had sold between $15,001 and $50,000 in Amgen stock on October 15th.

Senator Sheldon Whitehouse also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 10/15/2026.
• Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 9/4/2026.
• Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 9/4/2026.
• Sold $15,001 – $50,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 9/4/2026.
• Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/13/2026.
• Sold $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/13/2026.
• Sold $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 8/13/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 8/12/2026.

Amgen Stock Up 3.7%

AMGN stock opened at $478.48 on Thursday. The stock has a market cap of $258.68 billion, a P/E ratio of 19.90, a PEG ratio of 3.38 and a beta of 0.43. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a twelve month low of $302.13 and a twelve month high of $482.48. The company’s 50 day moving average is $421.56 and its two-hundred day moving average is $376.90.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. Amgen had a return on equity of 128.15% and a net margin of 24.14%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.64 EPS. Research analysts expect that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is 62.65%.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is owned by insiders.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported adjusted earnings of $6.45 per share and revenue of $10.37 billion, topping analyst estimates; revenue increased 8.5% year over year. The company also raised its 2026 outlook to $38.9 billion–$39.7 billion in revenue and $18.34–$19.28 in GAAP EPS. Amgen third-quarter financial results
• Positive Sentiment: Growth in medicines including Repatha and IMDELLTRA helped offset pressure elsewhere. Amgen also highlighted pipeline progress, including IMDELLTRA and potential longer-term growth from its obesity candidate MariTide. Amgen raises 2026 outlook
• Positive Sentiment: Several firms raised their targets, including UBS and Scotiabank to $530 and Goldman Sachs to $536, with buy or outperform ratings. These revisions suggest some analysts see further upside after the results. Analyst views and revised targets
• Neutral Sentiment: Analyst opinion remains divided: some target increases still leave estimates below the prevailing share price, and MariTide data is a future catalyst rather than a near-term result. RBC Capital adjusts Amgen target
• Negative Sentiment: Investors remain concerned about steep declines in Prolia and Xgeva as biosimilar competition weighs on sales. That erosion may limit how much growth from newer products translates into future results. Sales and biosimilar concerns

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp increased its stake in shares of Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after acquiring an additional 11,656,755 shares in the last quarter. MW Advisory LLC bought a new position in shares of Amgen during the second quarter valued at approximately $1,054,000. Baird Financial Group Inc. lifted its holdings in shares of Amgen by 1.6% during the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock valued at $123,057,000 after purchasing an additional 5,496 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Amgen by 105.8% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock valued at $5,696,000 after purchasing an additional 6,947 shares during the last quarter. Finally, Nilsine Partners LLC bought a new stake in shares of Amgen in the 2nd quarter worth approximately $3,329,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Morgan Stanley upped their target price on Amgen from $359.00 to $410.00 and gave the company an “equal weight” rating in a research note on Wednesday. Guggenheim cut their price objective on shares of Amgen from $388.00 to $378.00 and set a “neutral” rating on the stock in a report on Tuesday, October 13th. Canaccord Genuity Group raised their target price on shares of Amgen from $384.00 to $440.00 and gave the stock a “hold” rating in a research report on Wednesday. Robert W. Baird boosted their target price on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. upped their price target on shares of Amgen from $350.00 to $425.00 and gave the stock a “neutral” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, seventeen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $413.38.

About Senator Whitehouse

Sheldon Whitehouse (Democratic Party) is a member of the U.S. Senate from Rhode Island. He assumed office on January 3, 2007. His current term ends on January 3, 2031.

Whitehouse (Democratic Party) ran for re-election to the U.S. Senate to represent Rhode Island. He won in the general election on November 5, 2024.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.